The Illegal Drug Marketplace in Your Patients’ Pockets

Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the…

Read More

What Should Health Care Do About AI’s Lack of Guardrails?

In another concerning example of AI agents going rogue recently, an OpenAI agent hacked into an Australian government website containing health care data. While some industry CEOs are calling for a slowdown and demands for regulation grow, host Chip Kahn focuses on the implications for health care when these same kinds of AI systems are…

Read More

Glucose Data Wants to Be Ambient

By IRAKLI KURTANIDZE I have lived with type 1 diabetes for more than twelve years, and I check my glucose the way most people check the time: dozens of times a day, in glances that last a second or two. A continuous glucose monitor sits on my arm and produces a fresh number every few…

Read More

DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens

DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data to provide insulin dosing recommendations for people with Type 2 diabetes who need both basal insulin and fast-acting injections. The post DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens…

Read More

Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology. The post Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch appeared first on…

Read More